Introduction: Despite major advances in lipid-lowering therapy, many patients continue to experience residual cardiovascular risk, particularly those with elevated triglyceride-rich lipoproteins and mixed dyslipidemia. Angiopoietin-like protein 3 (ANGPTL3) has emerged as an attractive therapeutic target because of its central role in regulating lipid metabolism.
Introduction:
Despite major advances in lipid-lowering therapy, many patients continue to experience residual cardiovascular risk, particularly those with elevated triglyceride-rich lipoproteins and mixed dyslipidemia. Angiopoietin-like protein 3 (ANGPTL3) has emerged as an attractive therapeutic target because of its central role in regulating lipid metabolism. Genetic studies have shown that reduced ANGPTL3 activity is associated with favorable lipid profiles and lower cardiovascular risk, prompting the development of several ANGPTL3-targeted therapies.
Problem Statement:
Although monoclonal antibodies, antisense oligonucleotides, and small interfering RNA therapies targeting ANGPTL3 have demonstrated promising lipid-lowering effects in individual clinical trials, the overall metabolic impact of this therapeutic class has not been comprehensively evaluated. Clarifying their efficacy across multiple lipid parameters is essential for understanding their potential role in cardiovascular risk reduction.
Summary:
This meta-analysis of randomized controlled trials provides a comprehensive assessment of the metabolic effects of ANGPTL3 inhibition. The analysis demonstrated that ANGPTL3-targeted therapies produce substantial reductions across a broad range of atherogenic lipoproteins, with particularly pronounced effects on triglyceride-rich lipoproteins. Significant improvements were observed in triglycerides, low-density lipoprotein cholesterol, apolipoprotein B, non-high-density lipoprotein cholesterol, very-low-density lipoprotein cholesterol, remnant cholesterol, and total cholesterol. Modest reductions were also noted in lipoprotein(a), an increasingly recognized cardiovascular risk factor. Importantly, ANGPTL3 inhibition achieved marked suppression of circulating ANGPTL3 levels, confirming effective target engagement. Differences among therapeutic approaches were observed, with the monoclonal antibody evinacumab demonstrating stronger reductions in several cholesterol-related parameters, while small interfering RNA agents showed particularly favorable effects on triglyceride-rich lipoproteins. Notably, no meaningful impact on systemic inflammatory markers was identified, suggesting that the benefits of ANGPTL3 inhibition are primarily mediated through lipid modification rather than anti-inflammatory mechanisms. These findings position ANGPTL3 inhibition as a promising strategy for patients with persistent dyslipidemia and residual cardiovascular risk, particularly those with elevated triglyceride-rich lipoproteins. Future outcome-driven studies will be essential to determine whether these impressive lipid improvements translate into meaningful reductions in cardiovascular events and long-term clinical benefit.
Introduction: Intrahepatic cholangiocarcinoma (ICC) is an aggressive primary liver cancer with poor prognosis and limited treatment options. While ICC has traditionally been considered a malignancy of biliary epithelial cells, increasing evidence suggests that hepatocytes can...
Introduction: Liver fibrosis is the key determinant of long-term outcomes in metabolic dysfunction-associated steatohepatitis (MASH). Activated hepatic stellate cells (HSCs) drive fibrogenesis, but effective antifibrotic therapies remain unavailable. This study investigated whether blocking the succinate–GPR91...
Introduction: The progression from metabolic dysfunction-associated fatty liver (MAFL) to metabolic dysfunction-associated steatohepatitis (MASH) is driven by complex interactions between hepatocytes and immune cells. This study identifies a novel spatial mechanism in the periportal (PP)...
Introduction: Cardiovascular–Kidney–Metabolic (CKM) syndrome recognizes the close interaction between obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease. This review highlights the emerging role of the gut microbiome, particularly butyrate-producing bacteria, as a central...
• Small intestinal adenocarcinoma (SIA) is a rare gastrointestinal cancer with limited disease-specific prognostic biomarkers and generally poor outcomes. • This nationwide Dutch population-based study evaluated whether three routinely available immunohistochemical markers—CK7, CK20, and CDX2—have...
Introduction: Metabolic dysfunction–associated steatotic liver disease (MASLD) is closely linked to insulin resistance and type 2 diabetes, with the liver traditionally viewed as a key regulator of blood glucose through hepatic glucose production. However, emerging...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.